![Důležité termíny](https://cdn.muni.cz/media/3633704/image_2.jpg?mode=crop¢er=0.5,0.5&rnd=133572412150000000&heightratio=0.5&width=278)
Informace o publikaci
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
Autoři | |
---|---|
Rok publikování | 2017 |
Druh | Článek v odborném periodiku |
Časopis / Zdroj | LEUKEMIA & LYMPHOMA |
Fakulta / Pracoviště MU | |
Citace | |
www | http://dx.doi.org/10.1080/10428194.2017.1298755 |
Doi | http://dx.doi.org/10.1080/10428194.2017.1298755 |
Obor | Onkologie a hematologie |
Klíčová slova | Carfilzomib; dexamethasone; bortezomib |
Popis | Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. |